Source comparison
Melanotan-2 Dosing and UV Exposure: Research Protocol Comparison
Conservative Escalation 0.25 mg days 1–3, 0.5 mg days 4–7, 0.75 mg days 8–14 10–15 min natural sun or 5–8 min UVA bed morning after injection Mild to moderate darkening in 60–70% of subjects (Fitzpatrick III–IV) 15–20% (mostly mild nausea) Recommended for firs
This comparison does not assign a generated winner or score.
- Conservative Escalation
- 0.25 mg days 1–3, 0.5 mg days 4–7, 0.75 mg days 8–14
- 10–15 min natural sun or 5–8 min UVA bed morning after injection
- Mild to moderate darkening in 60–70% of subjects (Fitzpatrick III–IV)
- 15–20% (mostly mild nausea)
- Recommended for first-time users. Minimises side effects while establishing baseline response
- Aggressive Front-Loading
- 1.0 mg daily from day 1
- Inconsistent or no structured UV exposure
- Minimal visible change in 40–50% of subjects despite high peptide dose
- 45–55% (nausea, flushing, fatigue)
- High dropout rate. Peptide activation without UV completion produces poor outcomes
- Maintenance-Only (No Loading)
- 0.5 mg twice weekly from day 1
- Daily 15–20 min sun exposure
- Delayed onset. Noticeable pigmentation by day 18–21, not day 14
- 8–12%
- Viable for subjects prioritising minimal side effects over rapid results
- High-Dose + Controlled UV
- 0.5 mg daily with 10 min UVA bed 12 hours post-injection
- Timed UVA exposure 12 hours after each injection
- Pronounced darkening in 75–80% of subjects by day 12–14
- 25–30% (mostly transient nausea)
- Fastest visible results but requires disciplined UV timing and tolerance for moderate adverse events